IRCT20200407046981N38尚未招募未知
Comparative bioequivalence study of the Empagliflozin 10 mg Tablets manufactured by Zist Arvand Pharmed Pharmaceutical Company
Zist Arvand Pharmed Pharmaceutical Company0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years（—）
- 性别
- Male
入选标准
- •The weight limit of each volunteer should be between 60 and 100 kg.
- •All volunteers must be non-smokers.
- •They must be healthy in terms of liver, kidney, respiratory system, mental and other general health characteristics that will be assessed.
- •Candidates who have consented to the consent form.
排除标准
- •Known hypersensitivity or idiosyncratic reaction to Empagliflozin or any ingredients.
- •Subjects with BP = 90/60 mm/Hg or BP = 140/90 mm/Hg.
- •Regular smoker who smokes more than ten cigarettes daily.
- •Taking any medicine during two weeks before dosing.
研究者
相似试验
招募中
不适用
Study of absorption and elimination rate of Empagliflozin tablets 25 mg in comparison with Empagliflozin brand tablets (Jardiance®).IRCT20200407046981N42Modava pharmaceutical company24
尚未招募
不适用
Comparative bioequivalence study of the Empagliflozin 25-mg Tablets manufactured by Rayhaneh Pharmaceutical CompanyBioequivalence study in healthy volunteers.IRCT20130313012810N17Rayhaneh Pharmaceutical Company24
尚未招募
不适用
Study of absorption and elimination rate of Empagliflozin tablets 25 mg in comparison with Empagliflozin brand tablets (Jardiance®).Bioequivalence study.IRCT20200407046981N36Darmanyab darou pharmaceutical company24
尚未招募
不适用
Study of absorption and elimination rate of Dapagliflozin 10-mg tablets in comparison with Dapagliflozin brand tablets (Farxiga®).Bioequivalence study.IRCT20200407046981N45Modava pharmaceutical company24
已完成
不适用
Comparative bioequivalence study of the Dapagliflozin 10-mg tablets manufactured by Noavaran Daroui Kimia CompanyIRCT20130313012810N5KIMIA Noavaran Daroui24